Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

An 8-year single institution review of demographic trends and treatment patterns among patients with anaplastic thyroid carcinoma.

Makayla Matthews, Victoria Fonseca, Jason Tasoulas et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18139

e18139 Background: Anaplastic thyroid carcinoma (ATC) is a rare entity with a dismal overall survival (OS) of <6 months. While historically, patients a...

Comparative survival outcomes among histological subtypes of pulmonary adenocarcinoma: A nationwide study.

Nouman Aziz, Waseem Nabi, Muzamil Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20066

e20066 Background: Adenocarcinoma of the lung is a heterogeneous malignancy with multiple histological subtypes. In the US, population survival outcomes a...

IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors.

Takahiro Kogawa, Seiichiro Mitani, David Berz et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3157

TPS3157 Background: B7-H3 is highly expressed in many solid tumors but has limited expression in normal tissues; high B7-H...

Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Kristina Fanucci, Amylou C. Dueck, Erica L. Mayer et al. Jun 01, 2025 pp. 526-526 10.1200/jco.2025.43.16_suppl.526

526 Background: The PALLAS trial (NCT02513394) investigated the efficacy of the addition of palbociclib (palbo) to standard adjuvant endocrine therapy (ET...

Unmasking the link between sleep apnea and lung cancer risk: A retrospective propensity-matched cohort study.

Mohammed Al-Nusair, Jowan Al-Nusair, Omar Obeidat et al. Jun 01, 2025 pp. 10558-10558 10.1200/jco.2025.43.16_suppl.10558

10558 Background: Obstructive sleep apnea (OSA) is a prevalent disorder characterized by intermittent hypoxia, systemic inflammation, hypercapnia, and oxi...

Promoting resilience in stress management within patients with early stage breast cancer.

Gabrielle Betty Rocque, Etzael Ortiz Olguin, Jessica M. Shuey et al. Jun 01, 2025 pp. 12109-12109 10.1200/jco.2025.43.16_suppl.12109

12109 Background: Women with breast cancer often experience persistent psychological distress, including fear of recurrence, which can be exacerbated in m...

Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.

Conor Ernst Steuer, Elizabeth E. Evans, Terrence Lee Fisher et al. Jun 01, 2025 pp. 103-103 10.1200/jco.2025.43.16_suppl.103

103 Background: Neoadjuvant treatment with immune checkpoint blockade (ICB) improves clinical benefit in patients with multiple types of cancers. Window o...

Oropharynx cancer in the US: Racial disparities in stage at presentation.

James Suggitt, Yingzhi Wu, Annu Singh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13766

e13766 Background: Global occurrence of oropharynx cancer (OPC) varies greatly. While rare in the US, the diverse nature of the US clinical environment –...

Transformer-based deep learning model for integrated pathomics and radiomics in predicting postoperative survival of intrahepatic cholangiocarcinoma patients.

Mingyu Wan, Yifei Shen, Nong Xu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16328

e16328 Background: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy with a dismal prognosis. While surgical resection stands as the...

Novel dendritic cells-targeting mRNA-LNP vaccine with potent anti-tumor activity in vivo.

Jiangli Gong, Jolanda Peng, Ronan Liu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21514

e21514 Background: Cancer vaccines have demonstrated limited efficacy in solid tumors with low immunogenicity. As the main antigen presenting cells, Dendr...

HIF family transcription factor expression in a cohort of 4362 patients with renal cell carcinoma (RCC).

Yu-Wei Chen, Shayan S. Nazari, Andrew Elliott et al. Jun 01, 2025 pp. 4543-4543 10.1200/jco.2025.43.16_suppl.4543

4543 Background: The HIF pathway drives RCC pathogenesis operating through transcription factors (TFs) that function as heterodimers of the oxygen-sensiti...

Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma.

Anqi Wang, Jinchang Lu, Tianqi Luo et al. Jun 01, 2025 pp. 11533-11533 10.1200/jco.2025.43.16_suppl.11533

11533 Background: Poly ADP-ribose polymerase (PARP) plays a role in DNA damage repair, and PARP inhibitors can exert anti-tumor efficiency in tumors with...

Enhancing recurrence detection in stage III colorectal cancer patients through molecular residual disease test-guided surveillance: A modeling study.

Sumeyye Samur, Emir Gursel, Ning Yan Gu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15600

e15600 Background: Colorectal cancer (CRC) is a prevalent solid tumor cancer. Patients remain at risk of recurrence despite curative-intent treatment. Ear...

IsoPSA in prostate cancer: A systematic review of diagnostic, prognostic and economic implications.

Pragya Jain, Nency Ganatra, Diksha Sanjana Pasnoor et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17166

e17166 Background: Prostate cancer (PCa) is the most commonly diagnosed cancer in men and 2nd leading cause of cancer-related deaths. Traditional Prostate...

Efficacy and safety of bevacizumab in combination with radiotherapy and temozolomide in patients with glioblastoma: A meta-analysis and meta-regression of randomized controlled trials.

Ibrahim Khalil, Umme Kulsum, Samiha Zaman Akhter et al. Jun 01, 2025 pp. 2057-2057 10.1200/jco.2025.43.16_suppl.2057

2057 Background: Glioblastoma (GBM), the most common primary brain tumor in adults, has a poor prognosis despite standard treatment. This meta-analysis ev...

Clinicogenomic features of non-small cell lung cancer patients with <i>BRAF</i> non-V600mutations.

Mohammad Freihat, Jiang Guanglong, Christopher A. Fausel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20519

e20519 Background: BRAF non-V600 alterations are uncommon in non-small cell lung cancer (NSCLC). Little is known about the clinical, genomic c...

Decoding oncology terminology: Using large language models for patient education.

Yuqing Wang, Inae Park, Jiahao Peng et al. Jun 01, 2025 pp. 10600-10600 10.1200/jco.2025.43.16_suppl.10600

10600 Background: Large language models (LLMs), such as OpenAI's ChatGPT-4, are designed to process natural language and generate responses to text-based...

Pembrolizumab monotherapy for melanoma or non-small cell lung cancer in India: Results of the phase IV keynote-593 study.

Sewanti Atul Limaye, Sameer Rastogi, Pratap K. Das et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21518

e21518 Background: The PD-1 inhibitor pembrolizumab has been shown to provide a significant overall survival (OS) benefit with manageable safety in global...

Comprehensive germline sequencing and MLPA analysis in breast cancer patients: 4 years of experience from an Indian cancer institute.

Bhuvan Chugh, Aditi Chaturvedi, Devavrat Arya et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12542

e12542 Background: This study captures the clinical data and prevalence of the various germline mutations across breast cancer patients in India. It provi...

AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.

Nicholas Cost, Lindsay A. Renfro, Matthew R. Zibelman et al. Jun 01, 2025 pp. 4521-4521 10.1200/jco.2025.43.16_suppl.4521

4521 Background: tRCC accounts for approximately 50% of pediatric RCC and 1-5% of RCC cases overall. tRCC, driven by TFE3 or...

Disparities in glioblastoma care: Insights from a nationwide survey.

Jacob Ellen, Quinn T. Ostrom, Fabio Iwamoto et al. Jun 01, 2025 pp. 11112-11112 10.1200/jco.2025.43.16_suppl.11112

11112 Background: Glioblastoma (GBM) care requires specialized, multidisciplinary management, often creating barriers to healthcare delivery and dispariti...

Decision analysis of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Xiaohong Chen, ZhiXin Li, Pingdong Li et al. Jun 01, 2025 pp. 6074-6074 10.1200/jco.2025.43.16_suppl.6074

6074 Background: Neoadjuvant therapy (NAT) with PD-1 inhibitors plus chemotherapy has been shown to have a high pathological response rate in LA HNSCC, bu...

Intraoperative radiation therapy versus partial breast irradiation for early-stage breast cancer: A global, propensity-matched retrospective cohort study.

Varada Salimath, Quaid Oza, Brittany Miles et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12530

e12530 Background: Intraoperative radiation therapy (IORT) and partial breast irradiation (PBI) are two modalities of radiation used in the treatment of b...

Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).

Joseph Patrick Erinjeri, Muhammad S. Beg, Mohamed Bouattour et al. Jun 01, 2025 pp. 4083-4083 10.1200/jco.2025.43.16_suppl.4083

4083 Background: In EMERALD-1 (NCT03778957), D + B + TACE significantly improved progression-free survival (PFS) vs TACE in participants (pts) with emboli...

Independent validation of a 16-protein test to assess malignant potential of small uveal melanocytic tumors.

David Alan Reichstein, Julia Litvinov, Olga Zolochevska et al. Jun 01, 2025 pp. 9590-9590 10.1200/jco.2025.43.16_suppl.9590

9590 Background: Uveal melanocytic tumors of indeterminate malignant potential (UMTIMP) are usually managed by a “watch and wait” approach before the deci...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page